Associated tags: Protein, Gene, Heart failure, Diabetes, Disease, Metabolism, Neuropathic pain, Pharmaceutical industry, Patient, Lexicon, Food, Hospital
Locations: THE WOODLANDS, TX, US, NEW YORK CITY, TEXAS
Shift,
FDA,
Albuminuria,
Investment,
Research,
Webcast,
Chronic kidney disease,
Endothelium,
PROGRESS,
American College of Cardiology,
ASN,
ID,
AAK1,
Overalls,
Heart failure,
Treatment,
Conference,
HCM,
Neuropathic pain,
Quality of life,
Diabetes,
Patient,
SGLT2 inhibitor,
Travel,
Diabetic ketoacidosis,
Obesity,
CKD,
Marketing,
Research and development,
American College,
Vessel,
Insulin,
Diabetes management,
Inhibitor,
NDA,
Coagulation,
Administration,
Society,
Lexicon,
Risk,
Growth,
Lexicon Pharmaceuticals,
Pharmaceutical industry Net sales for the quarter were $1.1 million reflecting 63 percent growth from the previous quarter.
Key Points:
- Net sales for the quarter were $1.1 million reflecting 63 percent growth from the previous quarter.
- Lexicon is initiating a Phase 3 study of sotagliflozin in HCM, with an expected study start mid-year 2024.
- Results from Two Large US Integrated Health System
Revenues: Revenues for the first quarter of 2024 were $1.1 million, primarily from the commercialization of INPEFA.
- Lexicon management will hold a live conference call and webcast today at 5:00 pm ET / 4:00 pm CT to review its financial and operating results and to provide a general business update.
THE WOODLANDS, Texas, April 18, 2024 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that senior company executives will be joined by leading physicians at the Lexicon 2024 Investor Day on April 22, 2024.
Key Points:
- THE WOODLANDS, Texas, April 18, 2024 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that senior company executives will be joined by leading physicians at the Lexicon 2024 Investor Day on April 22, 2024.
- The event will be held in New York City from 9:00 a.m. to 12:00 p.m.
- Business and scientific updates will be presented by Lonnel Coats, Lexicon’s chief executive officer; Jeff Wade, Lexicon’s president and chief financial officer; Alan Main, Ph.D., Lexicon’s executive vice president, innovation and chemical sciences; Tom Garner, Lexicon’s senior vice president and chief commercial officer; and Craig Granowitz, M.D., Ph.D., Lexicon’s senior vice president and chief medical officer.
- The corporate presentations and panel discussion with renowned medical leaders will highlight Lexicon’s strategy and efforts to address major areas of need in:
THE WOODLANDS, Texas, April 03, 2024 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced Jeff Wade, Lexicon’s president and chief financial officer, Tom Garner, Lexicon’s senior vice president and chief commercial officer, and Craig Granowitz, M.D., Ph.D., Lexicon’s senior vice president and chief medical officer, will participate in a moderated discussion at the 23rd Annual Needham Virtual Healthcare conference Wednesday April 10th, 1:30-2:10pm.
Key Points:
- THE WOODLANDS, Texas, April 03, 2024 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced Jeff Wade, Lexicon’s president and chief financial officer, Tom Garner, Lexicon’s senior vice president and chief commercial officer, and Craig Granowitz, M.D., Ph.D., Lexicon’s senior vice president and chief medical officer, will participate in a moderated discussion at the 23rd Annual Needham Virtual Healthcare conference Wednesday April 10th, 1:30-2:10pm.
- A simultaneous webcast will be available in the “Events” section of the Lexicon website at www.lexpharma.com/events , and a recording of the webcast will be available for two weeks following the original on-demand date.
Shift,
Protein kinase B,
Cardiology,
Stroke,
Health,
Myocardial infarction,
SGLT1,
Chronic kidney disease,
CKD,
Risk,
Theatre,
Endothelium,
Inflammation,
Knowledge,
SGLT2,
Diabetes,
HF,
University of Colorado,
Vessel,
University of Michigan,
Inhibitor,
University,
Coagulation,
Protein,
GDMT,
Heart failure,
American College,
Type 2 diabetes,
Vasodilation,
Food,
Hospital,
Pharmaceutical industry In a post-hoc analysis of data from the 10,584 patients in the SCORED Phase 3 clinical trial, 213 all-cause stroke events occurred, including 29 (13.6%) fatal events.
Key Points:
- In a post-hoc analysis of data from the 10,584 patients in the SCORED Phase 3 clinical trial, 213 all-cause stroke events occurred, including 29 (13.6%) fatal events.
- Sotagliflozin reduced the risk of all-cause stroke by 34%, with 1.2 events per 100 patient-years in the sotagliflozin group and 1.8 events per 100 patient-years in the placebo group.
- Similarly, sotagliflozin reduced the risk of ischemic stroke by 32%, with 0.8 events per 100 patient-years in the sotagliflozin group and 1.2 events per 100 patient-years in the placebo group.
- Candidate, University of Michigan, Ann Arbor, Michigan
Study researchers found that sotagliflozin inhibits platelet activation through simultaneously targeting SGLT1 and SGLT2.
Human,
Conference,
ATTD,
CKD,
Patient,
Diabetes,
EGFR,
Safety,
Chronic kidney disease,
DKA,
Hypoglycemia,
Pharmaceutical industry In this important patient population, treatment with sotagliflozin successfully lowered A1C, body weight, and systolic blood pressure with safety similar to the total study cohort.
Key Points:
- In this important patient population, treatment with sotagliflozin successfully lowered A1C, body weight, and systolic blood pressure with safety similar to the total study cohort.
- The efficacy and safety data were presented last week at ATTD 2024 - 17th International Conference on Advanced Technologies and Treatments for Diabetes in Florence, Italy.
- Relative to placebo, treatment with sotagliflozin led to similar reductions in A1C, body weight and systolic blood pressure in the CKD and total cohorts.
- “We are optimistic that sotagliflozin may become an important new treatment option for this important population.”
THE WOODLANDS, Texas, March 11, 2024 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) (“Lexicon”) today announced it has entered into a securities purchase agreement (the “purchase agreement”) for a private investment in public equity financing that is expected to result in gross proceeds of approximately $250 million, before deducting placement agent fees and offering expenses.
Key Points:
- THE WOODLANDS, Texas, March 11, 2024 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) (“Lexicon”) today announced it has entered into a securities purchase agreement (the “purchase agreement”) for a private investment in public equity financing that is expected to result in gross proceeds of approximately $250 million, before deducting placement agent fees and offering expenses.
- Subject to Lexicon stockholder approval, each share of Series A Convertible Preferred Stock will automatically convert into 50 shares of common stock.
- The private placement is expected to close on or about March 13, 2024, subject to customary closing conditions.
- The securities to be sold in the private placement have not been registered under the Securities Act of 1933, as amended (the “Securities Act”), or any state or other applicable jurisdiction's securities laws, and may not be offered or sold in the United States absent registration or an applicable exemption from the registration requirements of the Securities Act and applicable state or other jurisdictions' securities laws.
Chronic kidney disease,
Lexicon,
CRL,
New Drug Application,
FDA,
CKD,
Diabetes,
Patient,
Hearing,
NDA,
Pharmaceutical industry THE WOODLANDS, Texas, March 11, 2024 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), today announced that, following the receipt of recent feedback from FDA, it is preparing to resubmit its New Drug Application (NDA) for sotagliflozin as an adjunct to insulin therapy for glycemic control in patients with type 1 diabetes and chronic kidney disease (CKD). The resubmission is planned for mid-year, with an anticipated six-month regulatory review period.
Key Points:
- THE WOODLANDS, Texas, March 11, 2024 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), today announced that, following the receipt of recent feedback from FDA, it is preparing to resubmit its New Drug Application (NDA) for sotagliflozin as an adjunct to insulin therapy for glycemic control in patients with type 1 diabetes and chronic kidney disease (CKD).
- The resubmission is planned for mid-year, with an anticipated six-month regulatory review period.
- “We have remained steadfast in our support of sotagliflozin in type 1 diabetes and have worked diligently to identify a regulatory path forward for what we believe will be an important new therapy,” said Lonnel Coats, Director and Chief Executive Officer.
- Lexicon and FDA subsequently agreed in late 2023 to hold the NOOH proceedings in abeyance in order to engage in discussions regarding a path forward for resubmission and potential approval of the NDA.
Research,
New Drug Application,
American Heart Association,
Investment,
Obesity,
Growth,
EASD,
Arrowhead Conference,
Patient,
Chronic kidney disease,
Post hoc,
Neuropathic pain,
Marketing,
Heart failure,
Hypertension,
Hypertrophic cardiomyopathy,
Left ventricular hypertrophy,
NDA,
Express,
PROGRESS,
AAK1,
Risk,
Conference,
HCM,
Clinical trial,
Neuroscience,
Lexicon,
FDA,
Research and development,
Cardiology,
U.S. FDA,
Medicare,
Administration,
Travel,
Pharmaceutical industry Key Points:
- ET
THE WOODLANDS, Texas, March 11, 2024 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), today reported financial results for the three months ended December 31, 2023 and provided an update on key corporate milestones.
- “2023 was a pivotal year for Lexicon,” said Lonnel Coats, Lexicon’s chief executive officer.
- Unless otherwise stated, all comparisons are for the fourth quarter and full year of 2023 compared to the fourth quarter and full year of 2022.
- Revenues: Revenues for the fourth quarter and full year of 2023 were $0.7 million and $1.2 million, respectively, primarily from the commercialization of INPEFA.
Lithium,
UGT,
Risk,
Digoxin,
Shanda,
Hypotension,
FDA,
SGLT1,
Type 2 diabetes,
Acute kidney injury,
Congress,
Pyelonephritis,
Conference,
Fever,
Ketoacidosis,
Pregabalin,
Pregnancy,
Pain,
Assessment,
Gabapentin,
Tenderness,
New Drug Application,
Amber Grid,
HCM,
Common,
SGLT2,
PROGRESS,
Hypertrophic cardiomyopathy,
Diabetes,
Kidney,
Heart failure,
Dialysis,
History,
Patient,
Prescription,
Type,
Neuropathic pain,
Webcast,
Insulin,
T2DM,
EGFR,
Erythema,
T1DM,
Hypoglycemia,
Partnership,
Contraindication,
Diarrhea,
NDA,
Incidence,
Swelling,
Urinary tract infection,
Hospital,
Chronic kidney disease,
Internationalized domain name,
Metabolic acidosis,
Creatinine,
Growth,
Lactation,
Pharmaceutical industry THE WOODLANDS, Texas, Jan. 08, 2024 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), a biopharmaceutical company with a mission of pioneering medicines that transform patients’ lives, today announced a business and pipeline update at the 42nd Annual J.P. Morgan Healthcare Conference taking place January 8-12, 2024.
Key Points:
- THE WOODLANDS, Texas, Jan. 08, 2024 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), a biopharmaceutical company with a mission of pioneering medicines that transform patients’ lives, today announced a business and pipeline update at the 42nd Annual J.P. Morgan Healthcare Conference taking place January 8-12, 2024.
- “Lexicon achieved major advancements in 2023 in its business and pipeline of pharmaceutical innovations,” said Lonnel Coats, chief executive officer and director of Lexicon.
- The company will also focus on ensuring a strong ongoing awareness of INPEFA in the medical community through medical publications and congress presence.
- Company to Present at J.P. Morgan Healthcare Conference Thursday, January 11, 2024 at 10:30am PST (1:30pm ET)
Lonnel Coats, Lexicon’s chief executive officer, will make a company presentation.
Retrieved on:
Thursday, December 21, 2023
THE WOODLANDS, Texas, Dec. 21, 2023 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced its participation in the 42nd Annual JPMorgan Healthcare Conference taking place January 8 – January 12, 2024.
Key Points:
- THE WOODLANDS, Texas, Dec. 21, 2023 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced its participation in the 42nd Annual JPMorgan Healthcare Conference taking place January 8 – January 12, 2024.
- Lonnel Coats, Lexicon’s chief executive officer, will make a company presentation at 10:30am PT / 1:30 pm ET on Thursday, January 11th.
- Jeff Wade, Lexicon’s president and chief financial officer, Tom Garner, Lexicon’s senior vice president and chief commercial officer, and Craig Granowitz, M.D., Ph.D., Lexicon’s senior vice president and chief medical officer, will also participate in the presentation.
- A simultaneous webcast will be available in the “Events” section of the Lexicon website at www.lexpharma.com/events , and a recording of the webcast will be available for two weeks following the original on-demand date.
